157 related articles for article (PubMed ID: 26902765)
1. An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis.
Wiesholzer M; Pichler P; Reznicek G; Wimmer M; Kussmann M; Balcke P; Burgmann H; Zeitlinger M; Poeppl W
Antimicrob Agents Chemother; 2016 May; 60(5):2790-7. PubMed ID: 26902765
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
Kuti JL; Nightingale CH; Knauft RF; Nicolau DP
Clin Ther; 2004 Apr; 26(4):493-501. PubMed ID: 15189746
[TBL] [Abstract][Full Text] [Related]
4. Short versus long infusion of meropenem in very-low-birth-weight neonates.
Padari H; Metsvaht T; Kõrgvee LT; Germovsek E; Ilmoja ML; Kipper K; Herodes K; Standing JF; Oselin K; Lutsar I
Antimicrob Agents Chemother; 2012 Sep; 56(9):4760-4. PubMed ID: 22733063
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
Pai MP; Cojutti P; Pea F
Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal compared with intravenous meropenem for peritoneal dialysis-related peritonitis.
Vlaar PJ; van Hulst M; Benne CA; Janssen WM
Perit Dial Int; 2013; 33(6):708-9. PubMed ID: 24335130
[No Abstract] [Full Text] [Related]
8. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Krueger WA; Bulitta J; Kinzig-Schippers M; Landersdorfer C; Holzgrabe U; Naber KG; Drusano GL; Sörgel F
Antimicrob Agents Chemother; 2005 May; 49(5):1881-9. PubMed ID: 15855510
[TBL] [Abstract][Full Text] [Related]
9. Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem.
Conte JE; Golden JA; Kelley MG; Zurlinden E
Int J Antimicrob Agents; 2005 Dec; 26(6):449-56. PubMed ID: 16280244
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia.
Jaruratanasirikul S; Limapichat T; Jullangkoon M; Aeinlang N; Ingviya N; Wongpoowarak W
Int J Antimicrob Agents; 2011 Sep; 38(3):231-6. PubMed ID: 21726984
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of meropenem in patients undergoing automated peritoneal dialysis.
Ullah S; Ursli M; Fuhr U; Wiesholzer M; Kussmann M; Poeppl W; Zeitlinger M; Taubert M
Perit Dial Int; 2023 Sep; 43(5):402-410. PubMed ID: 37131320
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
Dandekar PK; Maglio D; Sutherland CA; Nightingale CH; Nicolau DP
Pharmacotherapy; 2003 Aug; 23(8):988-91. PubMed ID: 12921245
[TBL] [Abstract][Full Text] [Related]
13. A Nonparametric Pharmacokinetic Approach to Determine the Optimal Dosing Regimen for 30-Minute and 3-Hour Meropenem Infusions in Critically Ill Patients.
Mathew SK; Mathew BS; Neely MN; Naik GS; Prabha R; Jacob GG; K S; Fleming DH
Ther Drug Monit; 2016 Oct; 38(5):593-9. PubMed ID: 27454665
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection.
Jaruratanasirikul S; Sriwiriyajan S; Punyo J
Antimicrob Agents Chemother; 2005 Apr; 49(4):1337-9. PubMed ID: 15793108
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic/Pharmacodynamic Analysis of Meropenem for the Treatment of Nosocomial Pneumonia in Intracerebral Hemorrhage Patients by Monte Carlo Simulation.
Kong L; Tang Y; Zhang X; Lu G; Yu M; Shi Q; Wu X
Ann Pharmacother; 2017 Nov; 51(11):970-975. PubMed ID: 28677407
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of short versus extended infusion meropenem dosing in critically ill patients: a pilot study.
Langan KM; Jacob J; Li J; Nation RL; Bellomo R; Howden B; Johnson PD
Crit Care Resusc; 2014 Sep; 16(3):190-6. PubMed ID: 25161021
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.
Byun SY; Jeong JW; Choi JH; Lee KP; Youn HY; Maeng HJ; Song KH; Koo TS; Seo KW
J Vet Pharmacol Ther; 2016 Dec; 39(6):560-565. PubMed ID: 27302674
[TBL] [Abstract][Full Text] [Related]
18. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study.
Frippiat F; Musuamba FT; Seidel L; Albert A; Denooz R; Charlier C; Van Bambeke F; Wallemacq P; Descy J; Lambermont B; Layios N; Damas P; Moutschen M
J Antimicrob Chemother; 2015 Jan; 70(1):207-16. PubMed ID: 25216821
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion versus intermittent administration of meropenem in critically ill patients.
Thalhammer F; Traunmüller F; El Menyawi I; Frass M; Hollenstein UM; Locker GJ; Stoiser B; Staudinger T; Thalhammer-Scherrer R; Burgmann H
J Antimicrob Chemother; 1999 Apr; 43(4):523-7. PubMed ID: 10350382
[TBL] [Abstract][Full Text] [Related]
20. Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients.
Van Matre ET; Teitelbaum I; Kiser TH
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32122898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
